Genmab pipeline hype makes investment bank uneasy

The expectations for Genmab's pipeline are too high, says Germany-based investment bank Berenberg Bank, which has changed its share recommendation as it cannot justify the current pricing.
Photo: Lars Møller / Genmab / PR
Photo: Lars Møller / Genmab / PR
by marketwire, translated by catherine brett

Although Genmab has been called a "superstar" and "one of the best European biotech companies," Berenberg Bank has changed its recommendation to "sell", with a target price of DKK 2,200 (USD 334).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading